Table 2.
Data from Cardiovascular magnetic resonance imaging.
| c.95 A > G carriers n = 17 | c.95 A > G/RH n = 17 | c.95 A > G/c.95 A > G n = 17 | p-value | |
|---|---|---|---|---|
| Heart rate (min-1) | 70 (12) | 71 (15) | 64 (11) | 0.21 |
| LVEDV (mL m−2) | 82 (15) | 79 (16) | 87 (14) | 0.30 |
| LVESV (mL m−2) | 32 (8) | 30 (7) | 32 (6) | 0.82 |
| LVSV (mL m−2) | 51 (9) | 49 (11) | 55 (11) | 0.16 |
| LVCI (L min-1 m−2) | 3.5 (0.5) | 3.4 (0.9) | 3.5 (0.7) | 0.96 |
| LVEF (%) | 62 (5) | 61 (5) | 63 (5) | 0.52 |
| LV mass (g m−2) | 63 (11) | 60 (13) | 71 (14) | 0.037 |
| LV Peak Ejection Rate (ml s−1): | 567 (100) | 529 (152) | 581 (139) | 0.50 |
| LV Peak Filling Rate (ml s−1): | 537 (108) | 501 (150) | 616 (146) | 0.05 |
| LV Average wall thickening (%) | 71 (13) | 77 (16) | 76 (17) | 0.47 |
| LV Average wall motion (mm) | 8 (1) | 8 (1) | 9 (2) | 0.09 |
| Presence of fibrosis, n | 0 (0%) | 0 (0%) | 2 (12%) | 0.12 |
Data are presented as n (%) or mean ± standard deviation. LV, left ventricle; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVSV, left ventricular stroke volume; LVEF, left ventricular ejection fraction; c.95 A > G carriers, heterozygote; c.95 A > G/RH, compound heterozygotes for c.95 A > G and the risk haplotype; c.95 A > G/c.95 A > G, homozygote. P-values are from an ANOVA analyses or the χ² test as relevant. A p-value < 0.05 are considered significant.